That's a wrap!

Thank you for joining us!

Our 2022 KNOW YOUR NETs Virtual Patient and Family Education Conference was our most sucessful one yet! More than 700 people registered for the virtual program and we hope that the day's topics covered what you wanted to learn. Please take a moment to take our post-conference survey here to let us know what you liked, didn't like, and any suggestions for future content.

Lastly, we send a final and heartfelt "thank you" to our incredible co-sponsor the University of Chicago Medicine and all our educational partners. Our entire conference is available for viewing on our YouTube channel.

From experience to education:

How one family's NET experience led to better educational resources for NET patients and families.

"In 2012, my husband was diagnosed with a neuroendocrine tumor (NET) cancer. At that time, there was little information and few treatment options," said Suzanne Ludlow, NETRF Board Member and generous benefactor of NETRF's second edition of "Neuroendocrine Cancer: A Guide for Patients and Families."

Suzanne lost her beloved husband Vincent in 2017, but she's honoring his life while supporting other patients and families navigating NETs as a new member of the NETRF Board of Trustees. Read more about Suzanne and Vincent's story here.

Learn about NET Research in NETWise Episode 19

While we are busy wrapping up part two of our podcast discussing NET research, we invite you to listen to part one and then test your knowledge!

Advancing NET research is the core of our mission, and it’s a crucial need, because NETs are extremely complicated cancers and there is still a lot the medical community needs to learn about them. Listen here.

Understand research? Test your knowledge!

Once you've listened to part one of our NETWise Podcast about research, test your knowledge by taking the LACNETS NET Quiz here.

Lutathera Update

Novartis has resumed production and delivery of Lutathera following a production shutdown at its New Jersey and Italy sites in May. Novartis said at that time that it voluntarily suspended production to address potential quality issues in its manufacturing process and launch a thorough review.

Novartis has resumed delivery of Lutathera through a phased approach, working with physicians and providers. Screening and enrollment for clinical trials has also started again. Novartis said in a statement that it has resolved the issues that led to the temporary shutdown and no risk to patients from the doses previously produced was identified.

If you have questions about the availability of Lutathera in your area or your specific treatment schedule, please talk with your care team.

NETRF 2021 Annual Report

In case you missed it, we're sharing the link to our 2021 Annual Report dedicated to the transformational support from the Robert E. & Margie Petersen Foundation.

Learn about the remarkable lives of Robert and Margie Petersen, read about how NETRF funding from the Petersen Foundation changed the career trajectory of three researchers and learn how two donors are keeping NETRF in their charitable giving futures.

Donor support is critical to our mission to build a better future for people living with NETs. Please make your donation by clicking the button below.

DONATE

Studying Terbium-161 for treatment of NETs.

A new clinical trial being conducted at a single center in Switzerland aims to explore a therapy using a novel somatostatin receptor subtype 2 antagonist labelled with Terbium-161 (161Tb-DOTA-LM3). The study is sponsored by University Hospital, Basel, in collaboration with the Swiss National Science Foundation and the Paul Sherrer Institute and builds upon research funded by NETRF. Read more here.

TRACK Study:

Matched molecular therapy for patients with rare cancers

A patient advocacy-led clinical research study aims to determine if patients who have rare tumors can benefit from matched molecular therapy based on the results of their genomic profiling. Patients with neuroendocrine tumors and unknown primaries may be eligible for this study.

Sponsored by the TargetCancer Foundation, in collaboration with Foundation Medicine Inc., the TCF-001 TRACK (Target Rare Cancer Knowledge) Study uses next-generation sequencing to develop a comprehensive genomic profile of each participant’s tumor as well as their plasma circulating cell-free DNA (blood).

Hitting the links

for NETRF

On a beautiful summer day in Falmouth Massachusetts, 80 golfers gathered for a little friendly competition to raise money for NETRF in honor of Judith Jones, who lost her 20-month battle with neuroendocrine cancer in 2020.

Organized by her husband, children and her cherished grandchildren (pictured at right) the JJ Open to Support NETRF raised just about $8,400, which brings the Judith Jones Everlasting Impact Fund to over $21,000, exceeding their original goal of raising $20,000.

To learn more about ways to honor a loved one click here.

Special thanks to Advanced Accelerator Applications and IPSEN for sponsoring this July E-Newsletter

Give us a follow!

NETRF news and updates are available on our social channels, too. Like and follow us on Facebook, Instagram and Twitter!

DONATE

The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. To learn more,
view our Audited Financial Statements and IRS Form 990.

Manage your preferences | Opt out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.

31 St. James Avenue, Suite 365
Boston, MA | 02116 US

This email was sent to .
To continue receiving our emails, add us to your address book.